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Hermansky–Pudlak syndrome (HPS) (MIM #203300) is a heterogeneous group of autosomal recessive disorders
characterized by oculocutaneous albinism (OCA), bleeding tendency, and lysosomal dysfunction. HPS is very
common in Puerto Rico (PR), particularly in the northwest part of the island, with a frequency ofB1:1,800. Two
HPS genes and mutations have been identified in PR, a 16-base pair (bp) duplication in HPS1 and a 3,904-bp
deletion in HPS3. In Puerto Ricans with more typical OCA, the most common mutation of the tyrosinase (TYR)
(human tyrosinase (OCA1) gene) gene was G47D. We describe screening 229 Puerto Rican OCA patients for
these mutations, and for mutations in the OCA2 gene. We found the HPS1 mutation in 42.8% of cases, the HPS3
deletion in 17%, the TYR G47D mutation in 3.0%, and a 2.4-kb deletion of the OCA2 gene in 1.3%. Among Puerto
Rican newborns, the frequency of the HPS1 mutation is highest in northwest PR (1:21; 4.8%) and lower in central
PR (1:64; 1.6%). The HPS3 gene deletion is most frequent in central PR (1:32; 3.1%). Our findings provide insights
into the genetics of albinism and HPS in PR, and provide the basis for genetic screening for these disorders in
this minority population.
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INTRODUCTION
Hermansky–Pudlak syndrome (HPS) (MIM #203300) is a
genetically heterogeneous group of autosomal recessive
disorders characterized principally by oculocutaneous albin-
ism (OCA), bleeding tendency, and progressive pulmonary
fibrosis (Hermansky and Pudlak, 1959). HPS is a rare genetic
disease worldwide, but it is the most common single-gene
disorder on the island of Puerto Rico (PR), particularly in the
northwest region, where it occurs with a frequency of 1:1,800
(Witkop et al., 1990a, b). HPS thus represents a significant
public health problem in PR (Witkop et al., 1990a; Spritz,
1998). Other forms of OCA also occur in PR, but are much
less common (Witkop et al., 1990a).
The consequences of reduced skin pigmentation in OCA
and some forms of HPS, particularly photosensitivity and
social stigmatization due the noticeable skin color differ-
ences, are relatively significant in PR, where the sun exposure
rate is high and where relatively dark skin pigmentation is the
norm. Ocular consequences of OCA are typical in PR,
including low vision, nystagmus, strabismus, and photopho-
bia (Izquierdo et al., 1995), again exacerbated by the high
level of ambient sunlight. The systemic complications of HPS
are a particular problem; average patient survival is 30–50
years, death usually resulting from restrictive lung disease
(68%), hemorrhage (17%), or granulomatous colitis (15%)
(Witkop et al., 1990a). There is no specific or effective
treatment for most of the manifestations of HPS, although
pirfenidone may slow the progression of pulmonary fibrosis
(Gahl et al., 2002).
Studies of OCA and HPS patients from around the world
have demonstrated considerable genetic heterogeneity, with
four genes known to cause OCA and seven known to cause
HPS in humans (Spritz et al., 2003; Bonifacino, 2004). Early
premolecular epidemiologic studies in PR (Witkop et al.,
1990a, b) estimated that, among 349 patients with albinism,
there were five types of OCA and two types of ocular
albinism: 12% were considered to have OCA1, 4.9% OCA2,
0.6% OCA3, and 80–83% HPS, mostly from northwest PR.
HPS in PR was subsequently shown to result from founder
effects for single mutations of two genes, HPS1 and HPS3,
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which facilitated localization and identification of these
genes by linkage disequilibrium mapping and positional
cloning (Fukai et al., 1995; Wildenberg et al., 1995; Anikster
et al., 2001). Puerto Rican HPS1 patients have all been
homozygous for a 16-bp duplication/frameshift in the HPS1
gene (Oh et al., 1996) and Puerto Rican HPS3 patients have
all been homozygous for a 3,904-bp deletion in the HPS3
gene (Anikster et al., 2001). Similarly, a single mutation of the
tyrosinase (TYR, human tyrosinase (OCA1) gene) gene,
G47D, was found to be prevalent among northwest Puerto
Rican patients with OCA1 (Oetting et al., 1993). This
mutation has been found in many populations around the
world, and may have been propagated by Spanish sailors.
We have studied the clinical manifestations and molecular
genetics of OCA1 and 2 and HPS type 1 and 3 in San Juan,
PR. Our objectives were as follows: to determine the
prevalence of HPS1 and 3 among patients with OCA referred
to the outpatient clinics of the University of Puerto Rico
School of Medicine; to determine the presence of the HPS1
gene 16-bp duplication, the HPS3 gene 3,904-bp deletion,
and the presence of TYR and human pink-eyed dilution
(OCA2) gene (P) mutations among Puerto Ricans with OCA;
and to determine the carrier frequencies of the two common
HPS1 and HPS3 mutations among Puerto Rican newborns.
RESULTS AND DISCUSSION
We studied a total of 229 (114 male and 115 female patients)
unrelated Puerto Rican patients presenting with albinism.
Patients’ ages ranged from 1 month to 58 years (mean
8.24710.34 years). We studied a total 585 individuals in the
229 families. In families with multiple affected members,
only one affected individual was included in the study group.
All cases appeared consistent with autosomal recessive
inheritance, although two families exhibited apparent pseudo-
dominance due to an affected parent. Indeed, 80% of families
reported albinism in the extended family, such as probands’
cousins, aunts, uncles, or grandparents, suggesting that the
frequency of disease alleles is relatively high on the island.
We observed considerable phenotypic heterogeneity
among the study patients. All patients had low vision with
reduced visual acuity, nystagmus, and photophobia. Appar-
ent skin pigmentation was greatly reduced or absent among
patients subsequently found to have OCA1 or OCA2. In
contrast, skin hypopigmentation was quite variable and often
subtle among patients subsequently found to have HPS3,
although patients were invariably less pigmented than their
parents or unaffected sibs. Three family members of HPS3
patients were found to have undiagnosed HPS3 when genetic
testing was carried out and homozygosity for the HPS3 gene
3,904-bp deletion was established. These three cases had
nystagmus, very mild hypopigmentation, and ocular albinism
as well as easy bruising.
As most of the HPS patients studied here were children,
the severe clinical manifestations of HPS were not found as
often as reported in older patients. The most common
respiratory symptoms among the pediatric HPS patients
included rhinitis, cough, and bronchial wheezing; some
patients had been diagnosed with bronchial asthma. Four
patients with HPS3 had colitis or gastrointestinal bleeding of
unknown etiology at very early ages, including one patient at
birth and one prior to 2 years of age. Two out of these four
patients who presented lower gastrointestinal bleeding and/or
colitis were considered to have mild bleeding associated to
the bleeding diathesis. Their signs and symptoms disappeared
promptly; thus, they were not evaluated further. However,
in the other two patients, the signs and symptoms were
significant enough to get gastrointestinal bleeding consulta-
tion and biopsy. In these two cases (ages 5 and 20 years,
respectively), the gastrointestinal bleeding biopsy was
reported by an experienced pathologist as colitis.
These patients are being followed by pediatric and adult
gastroenterologists.
Approximately half of the 229 patients with OCA included
in this report were cases referred directly to the genetics
laboratory in our institution by ophthalmologists who asked
for HPS genetic testing. Most of these patients were not
available for evaluation in our hematology service. Out of the
229 albino patients reported in our article, 109 (47%), most
of them with a variable bleeding diathesis, were tested for
bleeding time (BT) and/or platelet aggregation tests. Forty-
nine of these 109 (45%) were homozygous for the HPS1 gene
16-bp duplication and 16 (32.7%) for the HPS3 gene 3,904-
bp deletion. Thirty-nine out of these 49 (79.6%) HPS type 1
patients had an abnormal BT, and 13 of the 16 patients with
HPS3 (81.2%) had an abnormal result.
Platelet aggregation tests were performed in 33 of the 49
HPS type 1 cases, out of which 26 (79%) had an abnormal
aggregation test with two or more platelet aggregation agents.
Similarly, among the 16 HPS3 patients, 13 (77%) showed
abnormal aggregation with two or more platelet agonists.
These hematological tests were also performed in a group
of 16 albino patients who did not have homozygous HPS1 or
HPS3 gene mutations, including five OCA1 and two OCA2
patients, and nine cases who were heterozygous for the HPS1
or HPS3 gene mutations frequent among Puerto Rican
patients. The BT was normal in all five homozygous OCA1
and two OCA2 patients tested. Similarly, the platelet
aggregation tests were normal in two out of three OCA1
and in both OCA2 patients tested. Corresponding tests
performed in the nine patients who were heterozygous for
the HPS1 gene 16-bp duplication showed that six had
abnormal BTs, and two out of four (who reported mild to
moderate bleeding diathesis) also had an abnormal platelet
aggregation.
We tested patient DNA samples for the most common
Puerto Rican HPS mutations and, in some cases, screened for
additional mutations in the HPS1, TYR, and OCA2 genes.
Patients who were heterozygous for the HPS1 gene 16-bp
duplication or the HPS3 3,904-bp deletion were screened for
mutations in the HPS1, OCA1, and OCA2 genes by exon
screening. Those who were heterozygous for the HPS1 gene
16-bp duplication were also screened for the HPS3 gene
3,904-bp deletion. No exon screening of the HPS3 gene was
performed, since we had only two cases of patients
heterozygous for the HPS3 gene 3,904-bp deletion. Among
the 229 unrelated albinism probands, 98 (42.8%) were
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homozygous for the common Puerto Rican HPS1 gene 16-bp
duplication (Oh et al., 1996) (Table 1). Another 11 patients
(4.8%) were heterozygous for this mutation (Table 1); exon
screening and sequencing detected no other pathologic
mutations of the HPS1 gene in these patients. In toto,
47.5% of patients were either homozygous or heterozygous
for the common HPS1 duplication. HPS type 1
thus comprised the major apparent OCA disorder in this
study, principally (490%) involving patients derived from
northwest PR.
An additional 39 (17%) patients were homozygous for the
common HPS3 gene deletion (Anikster et al., 2001); two
(0.9%) were heterozygous for this mutation. Nineteen
(B49%) of these cases were from central PR and the rest
were from various townships, including Ponce, Salinas,
Patillas, Cayey, Cidra, Bayamo´n, Caguas, San Lorenzo, Toa
Alta, and San Juan. These findings indicate that this mutation
probably arose in central PR, but is now distributed widely
across the island.
Analysis of the principal OCA genes (TYR and P/OCA2) by
exon screening and/or mutation-specific multiplex PCR
detected seven patients (3.0%) homozygous for the TYR
G47D mutation. This mutation, originally observed in
Caucasian patients, was subsequently observed in 11 Puerto
Rican OCA1 patients (Oetting et al., 1993) and was attributed
to migration to PR from the Canary Islands. However, the
G47D mutation is also extremely common among Moroccan
Jews (Gershoni-Baruch et al., 1994), and it may alternatively
be that this mutation was introduced to PR from the Canary
Islands, and to North Africa directly from Spain or via some
other route. Whatever its origin, the G47D mutation appears
to be the most common TYR gene mutation among Puerto
Ricans with OCA1.
Three patients (1.3%) were found to be homozygous, and
14 (6.1%) heterozygous, for the OCA2 2.7-kb deletion
commonly found in African (Spritz et al., 1995; Stevens
et al., 1997) and African-American (Lee et al., 1994; Durham-
Pierre et al., 1996) patients with OCA. This is the first report
of the 2.7-kb P/OCA2 gene deletion in PR, although the
finding of this mutation in PR is not surprising given the
historical admixture of Africans into the Puerto Rican
population (the slave trade in PR began in the early 16th
century (Izquierdo et al., 1993), principally from central west
Africa and Bantu-speaking Africa (Nagel and Ranney, 1990)).
The OCA2/P gene deletion is remarkably frequent among the
Bantu-speaking peoples of Tanzania (Spritz et al., 1995) and
South Africa (Stevens et al., 1995).
To determine the frequency of the common HPS1 and
HPS3 mutant alleles in PR, we tested 2000 dried blood
samples of newborns from the indigenous island population
(indigenous meaning children born from Puerto Rican parents
living in the island of PR and not in the mainland United
States). As shown in Table 2, the frequency of the common
HPS1 gene 16-bp duplication allele is 0.0476 (1/21),
essentially as estimated by Witkop et al. (1990a, b) from
epidemiologic surveys of patients from northwest PR (Ta-
ble 2). The frequency of the HPS1 mutant allele is lower
among individuals from east and southeast PR. As expected,
the frequency of the HPS3 deletion allele is higher in the
central region of PR (1/32) than elsewhere on the island, and
is least prevalent (1/187) in northwest PR (Table 2). Interest-
ingly, the overall summary frequencies of the HPS1 and HPS3
mutant alleles for the island in toto are essentially identical –
1/59. The HPS1 16-bp duplication allele appears to be in
Hardy–Weinberg equilibrium in the populations of northwest
and central PR (Po0.05), but not in the total population and
that of the main region of the island (Supplementary
material). We do not know the reason for the discrepancies
between the observed and expected frequencies, which
could be due to one or more of the Hardy–Weinberg
conditions not having been met.
The genotype frequencies for the HPS1 gene mutation are
significantly different in the three principal geographic
regions of the island (w2¼28.8; P¼ 0.000; see Supplementary
material). These differences may be due to the founder effect
already demonstrated to be present in northwest PR for HPS,
which results in a high genotype frequency and an expected
difference in the genotype frequency in other regions of the
island. Alternatively, these differences may be due to recent
major changes in the population structure of the main region
and, thus, in the island as a whole. In contrast, the HPS3
deletion allele appears to be in Hardy–Weinberg equilibrium
in the three geographic regions of the island (w2o0.2, which
is  3:84, for Po0.05; see Supplementary material), which
suggests that conditions for Hardy–Weinberg equilibrium
were met.
Our findings provide insights into the genetic epidemiol-
ogy of albinism in PR. In the island of PR, HPS1 is the most
frequent cause of albinism, accounting for at least 43% of
cases, particularly among patients from the northwest part of
the island. HPS3 is next in prevalence, accounting for 17% of
the total, particularly among patients from central PR. Island-
wide, however, the carrier frequencies of the common HPS1
and HPS3 gene mutations were essentially equivalent (1/59).
The scientific literature contains many reports of the high
prevalence of HPS in northwest PR (Witkop et al., 1990a, b;
Table 1. Results of mutation analysis of the HPS1,





Homozygous HPS1 16-bp duplication 98 42.8
Heterozygous HPS1 16-bp duplication 11 4.8
Homozygous HPS3 3,904-bp deletion 39 17.0
Heterozygous HPS3 gene 3,904-bp deletion 2 0.9
Homozygous TYR G47D mutation 7 3.0
Homozygous OCA2/P gene 2.7-kb deletion 3 1.3
Heterozygous OCA2/P gene 2.7-kb deletion 14 6.1
Unidentified mutation 55 24.0
Total 229 100
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Oh et al., 1996; Anikster et al., 2001 and many others);
hence, the increased awareness of the high incidence of HPS
among Puerto Ricans in the island’s medical community has
increased the reporting of HPS in that region of the island,
where B17% of the island population resides. In contrast,
awareness of the existence of a second type of HPS in central
PR is low, and was not reported in the scientific literature
until 2001. The carrier frequency of the HPS1 gene 16-bp
duplication among newborns was higher in northwest PR
(1:21) than the carrier frequency of the HPS3 gene 3,904-bp
deletion in central PR (1:32), which can cause a higher
number of cases in this more densely populated region of the
island, in combination with occult or known inbreeding,
which has been reported in both types of HPS in Puerto Rican
patients. These facts, combined with the milder phenotype of
HPS type 3 in Puerto Rican patients, has contributed to HPS
cases not being properly diagnosed early in childhood, as
evidenced by the undiagnosed cases mentioned above and
may account for the difference in the number of HPS type 1
versus HPS type 3 cases referred to the genetics laboratory
reported here.
At least 3% of Puerto Rican albinism patients have OCA1,
principally involving the G47D substitution. At least 1.3% of
patients have OCA2, principally involving the 2.7-kb gene
deletion. Altogether, we were able to establish molecular
diagnoses for B64% of the albinism patients in our Puerto
Rican cohort. Another 12% had heterozygous mutations in
the HPS1, HPS3, or OCA2/P genes, but no second mutation
was found. These patients either had cryptic mutations that
were not detected by the PCR-based exon screening methods
used or are chance carriers and have mutations in other genes
not studied here. A total of 24% of patients had no detectable
mutations in any of the genes tested, and again either have
mutations not detected by the methods used here or have
mutations in other genes not studied.
Our data show that the HPS1 16-bp duplication mutation
is carried by 1/21 newborns in northwest PR, similar to the
previous estimate of 1/22 based on clinical survey (Witkop
et al., 1990b) and 1/59 on the island overall. Based on 2000
US Census data, we thus estimate that there may be 308–464
cases of HPS1 on the island. We also provide the first
estimate of the carrier frequency of the HPS3 gene deletion in
central PR – 1/32. Surprisingly, the carrier frequency of the
HPS3 deletion allele is also high in the main region – 1/52.
The majority of HPS3 cases may thus derive from areas of PR
other than the northwest or central regions. The results of our
mutation testing among newborns can be extrapolated to the
number of children born in the island each year (B50,000/
year). Assuming Hardy–Weinberg equilibrium, we estimate
that B7–8 children with HPS (HPS1 and HPS3) will be born
on the island each year.
Finally, because 490% of the patients in our study were
o18 years of age, some of the severe long-term complica-
tions of HPS, such as pulmonary fibrosis and granulomatous
colitis, were uncommon in our study population. In several
instances, patients’ relatives were identified as having OCA
only after the proband had been investigated due to clinical
hypopigmentation, bruising, low vision, or nystagmus. Thus,
some cases, particularly of the clinically milder HPS3, may
not be recognized until relatively late, even in adulthood. We
Table 2. Results of screening Puerto Rican newborns for the HPS1 gene 16-bp duplication and the HPS3 gene
3,904-bp deletion
HPS1 16-bp duplication genotype
Region of the






Northwest 379 19 0 398 0.9761 0.0239 1:1,751 4.8% (1:21)
Central 63 1 0 64 0.9922 0.0078 1:16,393 1.6% (1:64)
Main 1,533 14 1 1,548 0.9948 0.0052 1:37,223 0.9% (1:110)
Total 1,975 34 1 2,010 0.9910 0.0090 1:12,346 1.7% (1:59)
HPS3 3,904-bp deletion genotype
Region of the






Northwest 372 2 0 374 0.9973 0.0026 1:149,354 0.53% (1:189)
Central 62 2 0 64 0.9843 0.0156 1:4,110 3.1% (1:32)
Main 1,538 30 0 1,568 0.9904 0.0095 1:11,087 1.91% (1:52)
Total 1,972 34 0 2,006 0.9915 0.0084 1:14,211 1.7% (1:59)
NN=homozygous normal; NM=heterozygous for the mutation; MM=homozygous for the mutation.
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strongly recommend that all Puerto Ricans presenting with
even mild hypopigmentation, reduced visual acuity and/or
nystagmus, and easy bruising undergo molecular testing for
the common HPS1 and HPS3 gene mutations. These
evaluations will permit correct diagnosis, appropriate man-
agement, and genetic counseling of patients from this specific




This study group included children 0–18 years of age referred to the
Coagulation Clinic of the University of PR Pediatric Hospital in San
Juan, PR between 1997 and 2004 with either ocular albinism or
OCA. Some patients with ocular albinism or OCA were referred by
physicians at the Ophthalmology Clinics of the PR Medical Center,
Ponce School of Medicine, and the National Organization for
Albinism and Hypopigmentation-PR Chapter. All subjects were
Puerto Rican, and included both genders. Hematologic and
coagulation tests included complete blood count, prothrombin time,
activated partial thromboplastin time, BT, platelet aggregation tests,
and Factor VIII and von Willebrand factor activities. This study was
conducted according to the Declaration of Helsinki Guidelines for
the use of human subjects and was approved by the University of PR
Medical Sciences Campus Institutional Review Board. Participants
gave their written informed consent or assent.
DNA analyses
Genomic DNA was isolated from blood using QIAamp Blood Kits
(Qiagen, Valencia, CA). Purified DNAs were electrophoresed in 1%
agarose to assess DNA yield and quality, and DNA concentrations
were assessed by fluorometry using Hoechst 33258 dye and a
Hoeffer DynaQuant fluorometer (Cesarone et al., 1979). Samples
were stored at 701C until used. Exon 15 of the HPS1 gene was
amplified by PCR as described (Oh et al., 1996), and PCR products
were analyzed in 3.5% agarose gels (2% LM agarose, 1.5% agarose)
to separate the products of the normal (269 bp) and duplication
mutant (285 bp) alleles. The HPS3 gene 3,904-bp deletion was
assayed as described (Anikster et al., 2001) using 1.6% agarose gels.
Patients heterozygous for the common HPS1 mutation were further
studied by amplification of all exons and DNA sequence analysis as
described (Bailin et al., 1997).
We screened all HPS1 duplication-negative/HPS3 deletion-
negative patients for mutations in the HPS1, TYR (OCA1), and
OCA2/P genes by amplifying and directly sequencing exonic PCR
products (Oetting et al., 1991; Gershoni-Baruch et al., 1994; Lee
et al., 1995a, b). The common 2.7-kb OCA2/P gene deletion was
assayed as described (Durham-Pierre et al., 1996), and was
confirmed by direct automated DNA sequencing of the 420-bp
PCR product derived from the deletion allele using the Thermo-
Sequenase II sequencing kit (Amersham Biosciences, Piscataway, NJ).
Analysis of dried blood samples of newborns
Blood filters were obtained from newborns from the eight health
regions of the island of PR, using a randomized sampling method
based on the population distribution in the island reflected in the
2000 US Population Census and in the number of births registered
for each of the 46 PR hospitals with childbirth facilities. DNA was
extracted fromB2,000 dried blood samples of newborns on Guthrie
cards using Chelex resin (Dracopoli et al., 1998) and stored for less
than 1 month. PCR analyses were carried out as described (Oh et al.,
1996; Anikster et al., 2001), using 20 ml Chelex-extracted DNA.
To randomize the sampling, we collected samples sequentially
from the dried blood samples of the PR Newborn Screening Program
until the desired number was obtained, excluding samples that came
from individuals of ethnicities other than Puerto Rican. Three
geographic regions were defined for the purposes of this study,
following the regionalization of HPS1 and HPS3 in PR proposed by
Anikster et al. (2001). The northwest region includes 17 towns
(population 701,945, 18.43%), the central region includes four
towns (population 105,113, 2.8%), and the main region includes 57
towns (population 3,001,552, 78.8%) (see Supplementary Material
for details). The carrier frequency of HPS in northwest PR had been
estimated at 1:21 (Witkop et al., 1990a, b), which we used to
estimate the proportion of individuals carrying the HPS1 gene
mutation. The average number of live births per year in the island of
PR from 2001 to 2003 was 50,724 (PJ Santiago-Borrero, personal
communication). A sample of 2000 newborns thus represents 3.9%
of the average number of newborns in 2001–2003. We assumed that
the frequency of carriers in PR could not be higher than 0.05, for a
95% confidence interval with d¼ 0.01. We obtained a sample size
of n¼ 1,786, using the large sample normal approximation adjusted
for a finite newborn population size (N) of 50,000. Data were
analyzed using the Hardy–Weinberg equation and contingency
tables constructed using standard methods.
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SUPPLEMENTARY MATERIAL
Table S1. Names of Commonwealth of Puerto Rico towns included in the
geographic regions defined for the purposes of this study.
Table S2. Resuts of screening 2,010 Puerto Rican newborns for the HPS1
16-bp duplication.
Table S3. Results of screening 2,006 newborns for the HPS3 gene 3,904-bp
deletion.
Figure S1. Map of the US Commonwealth of Puerto Rico. The map shows the
location of the selected towns in the Northwest in gray, those in the Central
region in black and those in the Main region in white.
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